Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody

PURPOSE: Despite remarkable clinical responses and prolonged survival across several cancers, not all patients benefit from PD-1/PD-L1 immune checkpoint blockade. Accordingly, assessment of tumour PD-L1 expression by immunohistochemistry (IHC) is increasingly applied to guide patient selection, ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Christensen, Camilla, Kristensen, Lotte K., Alfsen, Maria Z., Nielsen, Carsten H., Kjaer, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101303/
https://www.ncbi.nlm.nih.gov/pubmed/31883023
http://dx.doi.org/10.1007/s00259-019-04646-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101303/
https://www.ncbi.nlm.nih.gov/pubmed/31883023
http://dx.doi.org/10.1007/s00259-019-04646-4

Ejemplares similares